ArticleProstate cancer and prostatic diseases2024

Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancer.

Mohamed E Ahmed et al.PubMed ↗Publisher ↗

No numbers read from the abstract.